HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintains a $32 price target.
May 10, 2024 | 7:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Iovance Biotherapeutics with a $32 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $32 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong conviction in the stock's potential for growth. This endorsement is likely to instill confidence among investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100